TD52 dihydrochloride(Cat No.:I043582)is a small-molecule compound being investigated for its potential therapeutic applications in cancer treatment. It functions as a potent inhibitor of specific kinases involved in tumor cell proliferation and survival, disrupting key signaling pathways essential for cancer growth. Preclinical studies suggest that TD52 dihydrochloride can suppress tumor growth in various cancer models, including solid tumors and hematological cancers. Its targeted mechanism of action holds promise for overcoming resistance to other therapies. Ongoing research is focused on evaluating its safety, efficacy, and potential for use in combination therapies in clinical settings.